Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS060304 in Healthy and Elevated LDL-C Subjects
NCT06485245Phase 1Active, not recruiting
- Sponsor
- Cascade Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cs060304 in Metabolic dysfunction-associated steatohepatitis (MASH) (10 cohorts), sponsored by Cascade Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Apr 2025; status: active, not recruiting.
02
Drugs
cs060304
03
Conditions
Metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06485245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485245.